Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Oliver Weigert, Vindi Jurinović et al.|The Lancet Oncology|2015Cited by 613
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, David M. Weinstock|The Journal of Experimental Medicine|2012Cited by 162
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Michael R. Green, Sreejoyee Ghosh et al.|Cancer Discovery|2020Cited by 159
BCL2 Suppresses PARP1 Function and Nonapoptotic Cell DeathChaitali Dutta, David M. Weinstock, Tovah A. Day et al.|Cancer Research|2012Cited by 54
Current treatment standards and future strategies in mantle cell lymphomaM. Dreyling, Wolfgang Hiddemann, Oliver Weigert|Annals of Oncology|2008Cited by 23